Report Summary 1. Report Industry Investment Rating No information provided on the report industry investment rating. 2. Report's Core View - Gold is expected to trade in a high - level range, while silver is expected to experience a slight decline [1] - The trend strength of gold is 1, indicating a relatively weak positive outlook; the trend strength of silver is - 1, indicating a relatively weak negative outlook [6] 3. Summary by Relevant Catalogs 3.1. Fundamental Tracking - **Precious Metal Prices**: - For gold, the previous day's closing prices of沪金2510 and黄金T+D decreased by 0.31% and 0.33% respectively, while Comex黄金2510 increased by 0.99% [2] - For silver, the previous day's closing prices of沪银2510 and白银T+D decreased by 1.57% and 1.74% respectively, while Comex白银2510 increased by 1.48% [2] - **Trading Volume and Open Interest**: - For沪金2510, the previous day's trading volume increased by 31,416 compared to the day before, and the open interest increased by 39 [2] - For沪银2510, the previous day's trading volume increased by 242,392 compared to the day before, and the open interest decreased by 23,822 [2] - **ETF and Inventory**: - The SPDR gold ETF持仓 decreased by 4, and the SLV白银ETF持仓 (the day before yesterday) decreased by 34 [2] - The沪金 inventory increased by 249 kilograms, while the Comex黄金 inventory (the day before) decreased by 17,426 ounces; the沪银 inventory decreased by 9,247 kilograms, while the Comex白银 inventory (the day before) increased by 600,232 ounces [2] - **Price Spreads**: - The买沪金12月抛6月跨期套利 cost decreased by 0.87, and the买沪银12月抛6月跨期套利 cost decreased by 11.3 [2] - The黄金T+D对伦敦金的价差 increased by 378.99, and the白银T+D对伦敦银的价差 increased by 4,670 [2] - **Exchange Rates**: - The dollar index decreased by 0.04%, and the dollar - to - CNY (CNY spot) decreased by 0.06% [2] 3.2. Macro and Industry News - The Fed's July meeting minutes showed that most people think inflation is a higher risk than employment, and there are concerns about the fragility of the US Treasury market and the impact of stablecoins [4] - Trump pressured the Fed, asking Lisa Cook to resign, but Cook refused to be coerced [7] - Fed Chair favorite Waller said there's nothing to fear about cryptocurrency technology and the Fed should promote payment innovation with the industry [7] - Li Qiang emphasized promoting the improvement and upgrading of the biopharmaceutical industry [7] - China's August LPR quotes remained unchanged, with the 5 - year - plus LPR at 3.5% and the 1 - year LPR at 3% [7] - The Hong Kong Stock Exchange will study a 24 - hour trading mechanism [5]

Core Insights - Jiangsu Province has 16 companies listed in the 2024 China Pharmaceutical Industry Top 100, an increase of one from the previous year, maintaining the highest number in the country for two consecutive years [1][2] - The province's biopharmaceutical cluster achieved over 450 billion yuan in revenue and over 73 billion yuan in profit, both ranking first in the nation [1] - Jiangsu's chemical drug sector surpassed 200 billion yuan, while the medical device sector exceeded 100 billion yuan [1] Industry Overview - The top 100 companies reflect the concentrated development of the pharmaceutical industry in Jiangsu, which has established a solid foundation and competitive advantage nationally [2] - The province has cultivated 8 national manufacturing single champion enterprises and 214 national specialized and innovative "little giant" enterprises [1] - Jiangsu's focus on collaborative innovation and support for innovative drug and medical device development is evident through policies that integrate resources from universities, research platforms, and hospitals [1][2] Company Performance - Among the listed companies, 9 are in the top 50, with Heng Rui Medicine and Zhengda Tianqing Pharmaceutical ranking 8th and 9th respectively [2] - Companies such as Innovent Biologics and Hansoh Pharmaceutical have made significant jumps in rankings, moving up 8 and 5 places respectively [2] - Jiangsu has 5 companies in the top 10 for "2024 R&D Intensity Industrial Enterprises," with Innovent Biologics leading the list [2] Future Outlook - The Jiangsu Provincial Industry and Information Technology Department plans to enhance the "1650" industrial system, focusing on platform synergy, mechanism empowerment, and ecological cultivation [2] - The goal is to strengthen inter-departmental collaboration, improve policy support systems, and accelerate the creation of a biopharmaceutical cluster with international competitiveness [2]

Group 1 - The core viewpoint of the news is the strategic R&D cooperation agreement between CSPC Pharmaceutical Group and AstraZeneca, with a total contract value of $5.33 billion for the discovery and development of new oral small molecule drug candidates using AI technology [1] - CSPC has previously licensed 11 products overseas, with a total contract value exceeding $7.3 billion, indicating a strong track record in international collaborations [1] - CSPC currently has over 200 innovative drug projects under research and ranks 19th in the global pharmaceutical R&D pipeline scale as of 2025 [1] Group 2 - Shijiazhuang City is actively promoting high-quality development in the biopharmaceutical industry, implementing comprehensive support measures across the entire lifecycle of the industry [1] - The city has revised and issued measures to support breakthroughs in the new generation of electronic information and biopharmaceutical industries, providing a total of 290 million yuan in rewards to biopharmaceutical companies since 2021, including 79.25 million yuan to CSPC [1] - Shijiazhuang City is committed to optimizing the business environment and has implemented targeted support for leading enterprises, addressing over ten operational issues for CSPC this year [1][2]

Core Viewpoint - The ninth BRICS Industrial Ministers' Meeting was held in Brasilia, focusing on topics such as digital transformation, smart manufacturing, and artificial intelligence, with an emphasis on cooperation among BRICS nations [1] Group 1: Emerging Field Cooperation - There is a commitment to strengthen cooperation in emerging fields, particularly in artificial intelligence, smart manufacturing, and biomedicine, to create a vibrant partnership [1] Group 2: Sustainable Development - The meeting encourages collaboration in sustainable development sectors, including new energy vehicles, photovoltaics, wind power, and hydrogen energy, aiming to jointly develop green technologies and high-quality products [1] Group 3: Industrial Capability Foundation - The BRICS nations aim to solidify their industrial capabilities by sharing experiences, promoting technology, coordinating standards, and training talent, thereby building a more resilient partnership [1] Group 4: Supply Chain Stability - There is a focus on maintaining the stability of industrial and supply chains, promoting a mutually beneficial industrial ecosystem, and fostering an open and united partnership [1]